DATROWAY
LaunchADCBLAINJECTIONINJECTABLEPriority Review
Approved
Jun 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
DATROWAY by Daiichi Sankyo is deruxtecan-dlnk, is a trop-2-directed antibody-drug conjugate. Approved for metastatic epidermal growth factor receptor (egfr)-mutated non-small cell lung cancer (nsclc), platinum-based chemotherapy, metastatic triple-negative breast cancer (tnbc) and 7 more indications. First approved in 2025.
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DATROWAY (datopotamab deruxtecan-dlnk) is a Trop-2-directed antibody-drug conjugate (ADC) combining a humanized anti-Trop2 IgG1 antibody with a topoisomerase I inhibitor payload (DXd) linked via a cleavable linker. It treats metastatic EGFR-mutated NSCLC, triple-negative breast cancer, and HR-positive/HER2-negative breast cancer by internalizing into tumor cells, releasing DXd to cause DNA damage and apoptosis. The mechanism provides selective tumor targeting with reduced systemic toxicity through intracellular payload release.
Growth
Recent launch (June 2025) with moderate competitive pressure (30/100) creates growth-phase opportunities for commercial expansion and field team development.
Mechanism of Action
deruxtecan-dlnk, is a Trop-2-directed antibody-drug conjugate. The antibody is a humanized anti-Trop2 IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Following binding to Trop-2 on cells, including tumor cells, datopotamab…
Worked on DATROWAY at Daiichi Sankyo? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.